Icrc-weyer.com - Icrc-weyer Gmbh Company News Section

Icrc-weyer Gmbh Information
  • Simone Ahrens
  • Boelschestrasse 2, Berlin, Germany
  • Phone: 4930577032280
  • URL: http://icrc-weyer.com
  • ICRC-Weyer is an established all-phase contract research organization (CRO) based in Berlin, Germany. The company was founded in 1993 by Prof. Dr. Geerd Weyer and offers services ranging from pre-clinical through to phase IV clinical trials. ICRC-Weyer provides complete turnkey solutions including data management, monitoring and medical review services for all stages of the clinical development process.

    ICRC-Weyer has special expertise in Advanced Therapies, Nutrition, CDISC Data Standards and Medical Review.
Icrc-weyer Gmbh Press Release -

Icrc-weyer.com

  • Clinical CRO ICRC-Weyer Enhance Pharmacovigilance Risk Management
  • The Berlin-based clinical contract research organization (CRO) ICRC-Weyer GmbH is adapting a process of integrating medical review procedures into Pharmacovigilance risk management, a method that will lead to better Pharmacovigilance practices.
  • ICRC-Weyer has made further enhancements to their Pharmacovigilance risk management. By integrating medical review procedures into the Pharmacovigilan ...
  • January 09, 2013
  • ICRC-Weyer Clinical CRO Looks Back At A Successful Year 2012
  • ICRC-Weyer GmbH, a clinical contract research organization (CRO) based in Berlin, Germany, has released its review of the year 2012, stating it has been a successful and exciting 12 months for everybody involved in the business. The company looks forward to more constructive partnerships and growth for the year ahead.
  • The management of ICRC-Weyer GmbH looks back at a successful year 2012, with a number of new collaborations and partnerships in the area of outsourcin ...
  • December 18, 2012
  • Clinical CRO ICRC-Weyer Ready For Increase In Advanced Therapy Trials
  • The clinical contract research organization (CRO) ICRC-Weyer GmbH, based in Berlin, Germany, has announced that the company is prepared for the increasing number of Advanced Therapy trials, a trend that is expected to continue for the next 10 to 15 years.
  • ICRC-Weyer's recent participation in the NanoKTN biotechnology meeting in Berlin proved to be both informative and successful. The event which took pl ...
  • September 26, 2012